PATENT CLAIM ANALYSIS

Application Number: 16007517
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "04400A"]

Abstract:
The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.

Claim (Index 2):
The composition of  claim 1 , wherein the composition further comprises a second RNAi agent to Beta-Catenin.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 94.0
- Lexical Diversity: 1.66197
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15834323', '14770765', '15587538', '13355930', '13355903']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7895819606280454
- 35 USC 102 Novelty (BERT): 0.5301204336897153
- Combined Prediction Score: 0.7636358079342125
- Mean Citation Score: 305.80274
- Max Citation Score: 357.64923
- Similarity Product: 334.8452868302285

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test